https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection

FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection

On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab.

administrator

Related Articles